Chronic Kidney Disease Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Pages: 92 Published: April 29, 2022 Report Code: GDHC244PIDR

The chronic kidney disease (CKD) market size was valued at $1.3 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 17% during the forecast period. Chronic kidney disease, or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, the symptoms worsen and eventually lead to kidney failure.

The chronic kidney disease market research report provides an overview of the risk factors, comorbidities, and global and historical trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for total prevalent cases and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age, sex, and stage in these markets.

Chronic Kidney Disease Market Overview

Chronic Kidney Disease Market Overview

To gain more information on the chronic kidney disease market forecast, download a free report sample

What are the key chronic kidney disease market drivers?

The major driver for the CKD market growth will be the increased use of drugs from different classes in combination with each other, which will lead to increased treatment costs. The uptake of sodium-glucose co-transporter inhibitors will be the strongest driver of the market in the 7MM. According to KOLs, combination therapy will become a mainstay in CKD treatment during the forecast period. This, in turn, will be the major driver of the market, despite the patent expirations of most currently marketed drugs and generic erosion.

What are the key age segments in the chronic kidney disease market?

The chronic kidney disease market can be segmented based on age into 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and above 80 years.

In 2021, for the 7MM combined, adults ages 70-79 years contributed the highest proportion of the diagnosed prevalent cases of chronic kidney disease followed by the age group 60–69 years and ages 80 years and older.

Chronic Kidney Disease Market Analysis by Age

Chronic Kidney Disease Market Analysis by Age

For more age segment insights, download a free report sample

What are the key sex segments in the chronic kidney disease market?

The chronic kidney disease market can be segmented based on sex into men and women.

In the 7MM combined, the number of diagnosed prevalent cases of CKD was higher in women than in men in 2021. However, in Germany and Japan, the number of diagnosed prevalent cases of CKD was observed to be higher in men than in women. France had the smallest variation in the number of diagnosed prevalent cases between men and women.

Chronic Kidney Disease Market Analysis by Sex

Chronic Kidney Disease Market Analysis by Sex

For more sex segment insights, download a free report sample

What are the key stages in the chronic kidney disease market?

The chronic kidney disease market can be further divided into six stages: stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V.

In the 7MM, the highest number of diagnosed prevalent cases of CKD was in stage IIIa followed by stages IIIb and stage II. Among the 7MM, Japan had the highest number of diagnosed prevalent cases of CKD in stage IIIa followed by the US. This difference in stage-specific diagnosed prevalent cases might be driven by the varying stage-specific diagnosis rate in the markets.

Chronic Kidney Disease Market Analysis by Stages

Chronic Kidney Disease Market Analysis by Stages

For more stage insights, download a free report sample

What are the key dialysis dependence types in the chronic kidney disease market?

The chronic kidney disease market can be divided into two types based on dialysis dependence: non dialysis dependent and dialysis dependent.

In the 7MM, the US had the highest number of diagnosed prevalent cases of CKD that were non-dialysis dependent followed by Japan and Germany. For dialysis-dependent CKD, the US had the highest number of diagnosed prevalent cases followed by Japan and Germany.

Chronic Kidney Disease Market Analysis by Dialysis Dependence

Chronic Kidney Disease Market Analysis by Dialysis Dependence

For more insights on dialysis dependence types, download a free report sample

Who are the key players in the chronic kidney disease market?

Some of the key players in the CKD market are AstraZeneca, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Reata Pharma, Novo Nordisk, and KBP- Biosciences.

Market report scope

  Market size (Year – 2021)  $1.3 billion
  Growth rate (CAGR)  >17%
  Forecast period 2021-2031
Key age segments 18-29 Years, 30-39 Years, 40-49 Years, 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 Years
Key sex segments Men and Women
Key stage Stage I, Stage II, Stage IIIa, Stage IIIb, Stage IV, And Stage V
Key dialysis dependence types Non-Dialysis Dependent and Dialysis Dependent
  Key players AstraZeneca, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Reata Pharma, Novo Nordisk, and KBP- Biosciences

Scope 

  • Overview of Chronic Kidney Disease- including epidemiology, disease etiology, and management.
  • Topline CKD drugs market revenue, the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5U, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global CKD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges

Key Highlights

The proportion of people at risk of developing CKD is expected to increase over the 10-year forecast period due to the growing disease prevalence.

The potential launch of 5 late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, novel drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.

Despite multiple therapies currently available to CKD patients, there is still a high level of unmet need within the treatment space. The most recognizable is the need for novel therapies targeting new mechanisms and improving access to novel therapies.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global CKD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CKD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global CKD therapeutics market from 2021 to 2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

  • AstraZeneca

    Boehringer Ingelheim

    Mitsubishi Tanabe Pharma

    Reata Pharma

    Novo Nordisk

    KBP- Biosciences

Table of Contents

| About GlobalData

1 Chronic Kidney Disease: Executive Summary

1.1 The CKD Market Will Exhibit Moderate Growth Between 2021 and 2031

1.2 Label Expansions of Anti-Diabetic Drugs Will Fuel Market Growth

1.3 Unmet Needs Remain in the CKD Market Despite the Availability of Well-Established Therapies

1.4 SGLT2 Inhibitors Will Likely Dominate Branded CKD Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 7MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Total Prevalent Cases of CKD

4.4.4 Total Prevalent Cases of CKD by Stage

4.4.5 Diagnosed Prevalent Cases of CKD

4.4.6 Diagnosed Prevalent Cases of CKD by Stage

4.4.7 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

4.5 Epidemiological Forecast for CKD (2021–31)

4.5.1 Total Prevalent Cases of CKD

4.5.2 Total Prevalent Cases of CKD by Stage

4.5.3 Diagnosed Prevalent Cases of CKD

4.5.4 Age-Specific Diagnosed Prevalent Cases of CKD

4.5.5 Sex-Specific Diagnosed Prevalent Cases of CKD

4.5.6 Diagnosed Prevalent Cases of CKD by Stage

4.5.7 Diagnosed Prevalent Cases of CKD by Dialysis Dependence

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Therapies for CKD Patients

7.3 More Effective Therapies for Patients with Renal Impairment

7.4 Preventative Therapies for Patients at Risk of Developing CKD

7.5 Optimal Management of CKD Treatments

8 R&D Strategies

8.1 Overview

8.1.1 Optimizing Treatment Safety and Compliance in Both the Pre-dialysis and Dialysis Setting

8.2 Clinical Trials Design

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 AstraZeneca

11.3 Boehringer Ingelheim

11.4 Mitsubishi Tanabe Pharma Corp

11.5 Reata Pharma

11.6 Novo Nordisk

11.7 KBP Biosciences

11.8 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Diagnosed Patients

13.3.3 Percent Drug-Treated Patients

13.3.4 Drugs Included in Each Therapeutic Class

13.3.5 Launch and Patent Expiry Dates

13.3.6 General Pricing Assumptions

13.3.7 Individual Drug Assumptions

13.3.8 Generic Erosion

13.3.9 Pricing of Pipeline Agents

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologists/Reviewers

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Chronic Kidney Disease: Key Metrics in the 7MM

Table 2: Stages of CKD

Table 3: KDIGO classification of CKD

Table 4: Risk factors and comorbid conditions associated with CKD

Table 5: Common Diagnostic Tests for CKD

Table 6: Treatment Guidelines for CKD

Table 7: AstraZeneca’s CKD Portfolio Assessment, 2022

Table 8: Boehringer Ingelheim’s CKD Portfolio Assessment, 2022

Table 9: Mitsubishi Tanabe’s Portfolio Assessment, 2022

Table 10: Reata’s Portfolio Assessment, 2022

Table 11: Novo Nordisk’s Portfolio Assessment, 2022

Table 12: KBP’s CKD Portfolio Assessment, 2022

Table 13: Chronic Kidney Disease Market – Global Drivers and Barriers, 2021–31

Table 14: Key Events Impacting Sales for Chronic Kidney Disease in the US, 2021–31

Table 15: Chronic Kidney Disease Market – Drivers and Barriers in the US, 2021–31

Table 16: Key Events Impacting Sales for Chronic Kidney Disease in the 5EU, 2021–31

Table 17: Chronic Kidney Disease Market – Drivers and Barriers in the 5EU, 2021–31

Table 18: Key Events Impacting Sales for Chronic Kidney Disease in Japan, 2021–31

Table 19: Chronic Kidney Disease Market – Drivers and Barriers in Japan, 2021–31

Table 20: Key Launch dates for CKD

Table 21: Key Patent Expiration Dates for CKD

Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Chronic Kidney Disease in 2021 and 2031

Figure 2: Analysis of the Company Portfolio Gap in Chronic Kidney Disease During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Chronic Kidney Disease During the Forecast Period

Figure 4: The Etiology of CKD

Figure 5: The Pathophysiology of CKD

Figure 6: 7MM, diagnosed prevalence of CKD (%), men, ages ≥18 years, 2021

Figure 7: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of CKD

Figure 8: 7MM, sources used to forecast the total prevalent cases of CKD by stage

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by stage

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by dialysis dependence

Figure 11: 7MM, total prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021

Figure 12: 7MM, total prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021

Figure 13: 7MM, diagnosed prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021

Figure 14: 7MM, diagnosed prevalent cases of CKD by age group, N, both sexes, 2021

Figure 15: 7MM, diagnosed prevalent cases of CKD by sex, N, ages ≥18 years, 2021

Figure 16: 7MM, diagnosed prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021

Figure 17: 7MM, diagnosed prevalent cases of CKD by dialysis dependence, N, both sexes, ages ≥18 years, 2021

Figure 18: 7MM, diagnosed prevalent cases of CKD based on dialysis-dependent subtype, N, both sexes, ages ≥18 years, 2021

Figure 19: Unmet Needs and Opportunities in CKD

Figure 20: Overview of the Development Pipeline in CKD

Figure 21: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Chronic Kidney Disease in the 7MM During the Forecast Period

Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Chronic Kidney Disease During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, SGLT2 inhibitors

Figure 25: Analysis of the Company Portfolio Gap in Chronic Kidney Disease During the Forecast Period

Figure 26: Global (7MM) Sales Forecast by Country for Chronic Kidney Disease in 2021 and 2031

Figure 27: Sales Forecast by Class for Chronic Kidney Disease in the US in 2021 and 2031

Figure 28: Sales Forecast by Class for Chronic Kidney Disease in the 5EU in 2021 and 2031

Figure 29: Sales Forecast by Class for Chronic Kidney Disease in Japan in 2021 and 2031

Frequently Asked Questions

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.